Long Covid (Individuals with Ongoing COVID-19 Symptoms) Ongoing Effects (COVID-19)

February 10, 2025 updated by: Ziya Yildiz

Comparison of Quality of Life and Functional Capacity of Long Covid Patients and Symptom-Free Volunteers: a Randomized Controlled Study

Persistent Covid-19 symptoms, known as long Covid, can impact healthcare provision. This study aimed to assess how symptoms persisting six months after Covid-19 affect quality of life and functional capacity.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Isparta, Turkey, 32000
        • Süleyman Demirel Univesity

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients who had an infection at Süleyman Demirel University Hospital at least 6 and up to 18 months ago and were re-admitted to the hospital due to symptoms were included.

Description

Inclusion Criteria:

  • The study included individuals who had Covid-19 disease at least 6-18 months ago, who agreed to participate, and who were diagnosed with Covid-19 by a health institu-tion during the disease period.

Exclusion Criteria:

  • Individuals who were not between the ages of 18-65, who had cognitive and commu-nicative impairments, and who had orthopedic and neurological limitations that would prevent them from performing physical activity were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
S-
Individuals who have not had symptoms for 6-18 months after Covid infection
Other: Evalation
Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
S+
Individuals with ongoing symptoms 6-18 months after Covid infection
Other: Evalation
Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional capacity, physical function, physical role difficulties, emotional role difficulties, pain and general health
Time Frame: 1 year
Functional capacity was affected more in the group whose symptoms persisted than in the group whose symptoms did not persist (p<0.05). Some of the SF-36 sub-parameters (physical function, physical role difficulties, emotional role difficulties, pain and general health) were found to be sig-nificantly more affected in participants with persistent symptoms (p<0.05).
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ziya Yildiz

Collaborators

Pamukkale University
Suleyman Demirel University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 25, 2021

Primary Completion (Actual)

December 2, 2022

Study Completion (Actual)

February 20, 2023

Study Registration Dates

First Submitted

July 29, 2024

First Submitted That Met QC Criteria

July 29, 2024

First Posted (Actual)

July 30, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 10, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SülDemirelUni_YildizA_002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe